Insulin Degludec vs Glucagon
Head-to-head comparison of Insulin Degludec (Insulin degludec (desB30, acylated ultra-long-acting insulin analog)) and Glucagon (Glucagon) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Insulin Degludec | Glucagon |
|---|---|---|
| Category | Diabetes & Metabolic | Diabetes & Metabolic |
| Full Name | Insulin degludec (desB30, acylated ultra-long-acting insulin analog) | Glucagon |
| Molecular Weight | 6103.9 Da | 3482.75 |
| Half-Life | More than 25 hours | 5-10 min |
| Amino Acids | 50 | 29 |
| Typical Dose | 0.1-0.2 U/kg once daily | 1 mg IM/SC for severe hypoglycemia or 3 mg intranasal |
| Route | Subcutaneous | IM|SC|IN|IV |
| Purity | ≥98% | ≥98% |
| Studies Count | 7000 | 93 |
| Research Status | Approved | Approved |
Insulin Degludec Benefits
- ✓Ultra-long basal coverage
- ✓Lower day-to-day variability
- ✓Reduced nocturnal hypoglycemia
- ✓Flexible dosing time
Glucagon Benefits
- ✓rapid hypoglycemia reversal
- ✓raises plasma glucose
- ✓useful in emergency rescue
Insulin Degludec Dosing
Inject SC once daily|Titrate to fasting glucose and HbA1c response|May be administered with flexible timing in adults
Glucagon Dosing
1 mg IM/SC|3 mg intranasal
Insulin Degludec Side Effects
- ⚠Hypoglycemia
- ⚠Injection-site reactions
- ⚠Weight gain
Glucagon Side Effects
- ⚠nausea
- ⚠vomiting
Research Overview
Insulin Degludec
Studies highlight prolonged action and lower glycemic variability compared with many other basal insulins. It is frequently used in research on ultra-long basal coverage and hypoglycemia reduction.
Glucagon
Clinical and emergency medicine use is well established for severe hypoglycemia, with newer stable formulations improving ease of administration.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.